{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Xifaxan&page=3",
    "query": {
      "intervention": "Xifaxan",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 79,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Xifaxan&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Xifaxan&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T10:04:26.101Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03219528",
      "title": "A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Rifaximin 550 MG",
          "type": "DRUG"
        },
        {
          "name": "Low FODMAP Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2018-02-13",
      "completion_date": "2024-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219528"
    },
    {
      "nct_id": "NCT00281502",
      "title": "The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Encephalopathy",
        "Hepatitis C",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Rifaximin (drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-12",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2010-11-05",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00281502"
    },
    {
      "nct_id": "NCT04674176",
      "title": "Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Weight Loss"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayhealth Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-01-01",
      "completion_date": "2022-01-01",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 1,
      "location_summary": "Dover, Delaware",
      "locations": [
        {
          "city": "Dover",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04674176"
    },
    {
      "nct_id": "NCT03529825",
      "title": "Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Microbial Colonization"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 26,
      "start_date": "2018-07-18",
      "completion_date": "2021-09-10",
      "has_results": false,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03529825"
    },
    {
      "nct_id": "NCT00364689",
      "title": "RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Lactulose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2006-08",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00364689"
    },
    {
      "nct_id": "NCT05071716",
      "title": "Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "Rifaximin SSD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 524,
      "start_date": "2022-04-07",
      "completion_date": "2025-09",
      "has_results": false,
      "last_update_posted_date": "2025-07-24",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 139,
      "location_summary": "Dothan, Alabama • Chandler, Arizona • Peoria, Arizona + 103 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05071716"
    },
    {
      "nct_id": "NCT01846806",
      "title": "The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2012-09",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2017-08-04",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846806"
    },
    {
      "nct_id": "NCT00686920",
      "title": "Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 322,
      "start_date": "2007-03-07",
      "completion_date": "2010-12-08",
      "has_results": true,
      "last_update_posted_date": "2019-08-14",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Aurora, California • Fresno, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00686920"
    },
    {
      "nct_id": "NCT06298409",
      "title": "Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Intestinal Bacterial Overgrowth"
      ],
      "interventions": [
        {
          "name": "CapScan collection capsule",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Envivo Bio Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 34,
      "start_date": "2024-02-15",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 1,
      "location_summary": "Mountain View, California",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06298409"
    },
    {
      "nct_id": "NCT03462966",
      "title": "Rifaximin on Visceral Hypersensitivity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Visceral Hypersensitivity",
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4,
      "start_date": "2018-07-01",
      "completion_date": "2021-11-19",
      "has_results": true,
      "last_update_posted_date": "2022-09-13",
      "last_synced_at": "2026-11-15T10:04:26.101Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03462966"
    }
  ]
}